Vaccines against Emerging and Reemerging Viral Diseases of Humans and Animals
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: closed (31 August 2017) | Viewed by 51615
Special Issue Editor
Interests: veterinary vaccines; adenovirus; porcine reproductive and respiratory virus
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Pandemic outbreaks of influenza and AIDS have cost the lives of millions of people. These events were caused by introductions of animal viruses into the human population. More recently, animal viruses such as SARS- and MERS-coronaviruses, Ebola virus, “swine flu” (H1N1) and “bird flu” (H5N1; H7N9), Nipah and Hendra viruses have killed thousands of people worldwide. It is clear that changes in our modern society and in climate create new opportunity for viruses to emerge. Also, these changes allowed the formerly range-restricted dengue, chikungunya, West Nile and Zika viruses to reemerge among major populations worldwide. In addition, emerging and reemerging virial infections cause significant economic damage to livestock industry. For instance, porcine epidemic diarrhea virus (PEDV) is estimated to kill 8 million piglets in the USA in 2014. There has been an extension of the geographic range of this virus and other animal viruses such as bluetongue, Rift Valley and African swine fever virus. In combating the global threat of these diseases, vaccines are the valuable tool. This special issue of Vaccines will cover vaccine development against newly emerged and re-emerged viruses of humans and animals.
Dr. Alexander Zakhartchouk
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Vaccines
- Viruses
- Zika
- Ebola
- Dengue
- Chikungunya
- West Nile
- SARS
- MERS
- Nipah
- Hendra
- pandemic influenza
- bluetonge
- Rift Valley
- African swine fever
- porcine epidemic diarrhea
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.